Core Insights - Eli Lilly (LLY) and AbbVie (ABBV) are prominent U.S. drugmakers with strong market positions and diverse therapeutic portfolios, including immunology, oncology, and neuroscience [1][2] - Lilly's success is driven by its GLP-1 drugs, Mounjaro and Zepbound, which accounted for over 50% of its total revenues in 2025 [3][4] - AbbVie has successfully transitioned from the loss of exclusivity of Humira by launching new immunology drugs, Skyrizi and Rinvoq, which generated $26 billion in sales in 2025 [12][13] Summary of Eli Lilly - Mounjaro and Zepbound generated combined sales of $36.5 billion in 2025, representing around 56% of total revenues [4][10] - Lilly's new drugs and obesity pipeline, including orforglipron, are expected to drive sales growth in 2026 [5][10] - The company is investing in a broad obesity pipeline with various oral and injectable medications [6][7] - Despite strong growth prospects, Lilly faces challenges such as declining product prices and rising competition in the GLP-1 market [11] Summary of AbbVie - AbbVie has effectively managed the impact of Humira's loss of exclusivity by launching Skyrizi and Rinvoq, which are expected to generate over $31 billion in sales in 2026 [12][13] - The neuroscience portfolio contributed to a 20% increase in sales, reaching $10.8 billion in 2025 [14] - AbbVie has been active in acquisitions to enhance its early-stage pipeline, investing over $5 billion in 2025 [15] - The company anticipates a revenue growth of approximately 9.5% in 2026, supported by strong performances from its new drugs [27][28] Financial Estimates and Valuation - The Zacks Consensus Estimate for Lilly's 2026 sales and EPS implies increases of 25.7% and 41.1%, respectively [17] - AbbVie's 2026 sales and EPS estimates suggest growth of 9.6% and 45.6%, respectively [19] - Lilly's stock has risen 9.2% over the past year, while AbbVie's stock has increased by 2.0% [22] - AbbVie appears more attractive from a valuation perspective, with a forward P/E ratio of 13.75 compared to Lilly's 25.12 [22][24]

Group 1: AbbVie - AbbVie is recognized as a reliable dividend raiser and is classified as a Dividend King, having raised its dividend annually for at least 50 years, although it is a spinoff from Abbott Laboratories [2] - Concerns arose earlier this decade regarding AbbVie losing patent exclusivity on its blockbuster drug Humira, but the company proactively strengthened its pipeline and made strategic acquisitions, introducing next-generation treatments Skyrizi and Rinvoq [3] - In the fourth quarter, Skyrizi and Rinvoq generated nearly $7.4 billion in net revenue, accounting for 44% of AbbVie's total revenue for that period [4] - AbbVie's neuroscience portfolio, led by the antipsychotic treatment Vraylar, also showed strong performance with a year-over-year revenue increase of 18%, totaling just under $3 billion [4] - The company's free cash flow is robust, supporting its long-standing dividend policy with a quarterly payout of $1.73 per share, yielding 3.4% [5] Group 2: Bristol Myers Squibb - Bristol Myers Squibb faces similar patent expiration challenges as AbbVie, particularly with its cancer drugs Revlimid and Opdivo [6] - The company is focusing on innovation within its oncology lineup, which is part of its growth portfolio, resulting in a 16% year-over-year revenue increase in the fourth quarter, reaching almost $7.4 billion [6]

Core Viewpoint - AbbVie is currently underperforming in the market, down 11% this year compared to the S&P 500's 4% decline, amid broader bearish sentiment in the healthcare sector due to concerns over healthcare reform and government cuts [1][2] Company Performance - AbbVie's revenue reached $61.2 billion in 2025, reflecting a 9% increase from the previous year, with a strong upward growth trend observed in recent quarters [4] - The company has adapted to challenges, including the loss of patent protection for its top drug, Humira, by successfully launching new immunology drugs, Skyrizi and Rinvoq, which generated $25.9 billion in revenue last year [3] Market Position - AbbVie is trading at a forward price-to-earnings multiple of 14, significantly lower than the S&P 500 average of 21, indicating it may be undervalued [7] - The price-to-earnings-growth (PEG) multiple stands at 0.49, suggesting the stock is cheap relative to expected growth, as a PEG below 1.0 is considered favorable [8] Future Potential - Despite current market conditions, AbbVie presents potential upside for investors, supported by an above-average dividend yield of 3.4%, making it an attractive long-term hold [9] - The company's diverse operations provide multiple avenues for growth, although aesthetics sales have declined by 6%, indicating potential for recovery as consumer spending increases [6]

Core Insights - AbbVie (ABBV) stock has recently slipped below its 50-day simple moving average (SMA), indicating short-term weakness, but remains above its 200-day SMA, suggesting a strong long-term uptrend due to solid fundamentals [1][8][30] Group 1: Drug Performance and Growth - AbbVie has successfully launched new immunology drugs, Skyrizi and Rinvoq, which generated combined sales of $26 billion in 2025, with expectations to exceed $31 billion in 2026, reflecting over 40% year-over-year growth [5][6][8] - The strong performance of Skyrizi and Rinvoq is driven by market share gains, new indications, and anticipated approvals for additional indications, potentially adding $2 billion to peak-year sales for Rinvoq [6][8] - AbbVie's neuroscience portfolio also contributed to growth, with sales increasing nearly 20% to $10.8 billion in 2025, driven by products like Botox Therapeutic and newer migraine treatments [9][10] Group 2: Challenges and Erosion - AbbVie faces challenges from the erosion of Humira sales, which declined around 50% in 2025 due to biosimilar competition, and is expected to continue declining in 2026 [16][28] - The aesthetics segment is also struggling, with global sales declining 5.9% in 2025, and expectations for flat growth in 2026 due to ongoing macro challenges [17][18] Group 3: Future Outlook and Investments - AbbVie anticipates total revenue growth of approximately 9.5% in 2026, driven by strong sales from Skyrizi, Rinvoq, and Vyalev, while facing headwinds from Humira erosion [28][29] - The company is on an acquisition spree, investing over $5 billion in innovative pipeline candidates to bolster long-term growth, particularly in immunology, oncology, and neuroscience [14][15] - AbbVie expects high single-digit revenue growth through 2029, with no significant loss of exclusivity events anticipated, allowing for increased R&D investments [29]

Core Thesis - AbbVie Inc. is viewed positively due to its successful transition from Humira, with a diversified drug portfolio and strong growth potential in the biopharmaceutical sector [1][6]. Financial Performance - AbbVie’s share price was $227.68 as of March 11th, with trailing and forward P/E ratios of 96.07 and 15.65 respectively [1]. - The company has seen its shares rebound, rising over 20% in 2025, indicating market confidence in its growth strategy [5]. Product Portfolio - AbbVie is navigating the post-Humira era by launching new therapies in immunology and oncology, with Skyrizi and Rinvoq generating combined sales of $6.9 billion [3][4]. - The company projects sales of $31 billion in 2027 and $40 billion by 2029 for its immunology drugs, indicating strong future revenue potential [4]. Pipeline and Development - AbbVie has an extensive pipeline with 20 drugs in phase III trials and over 50 in earlier development stages, targeting high-demand areas such as blood cancers and Parkinson's disease [4]. Dividend and Income Stability - AbbVie offers a $6.92 annual dividend, yielding 3.1%, and has a 53-year history of annual dividend increases, averaging 12.5% growth over the past decade [5].

Core Viewpoint - Large-cap biotech stocks are considered resilient to disruption risks typically faced by tech companies, primarily due to their long drug approval processes and established product portfolios [1][2] Group 1: Biotech Sector Resilience - Companies like Amgen and AbbVie are highlighted for their ability to navigate revenue erosion through broad product portfolios and multi-year pipeline replacements [1] - The FDA approval process, which can take a decade, provides a structural time buffer that protects biotech firms from rapid obsolescence [1] - Year-to-date performance shows Amgen up 16% and Gilead up 21% in 2026, significantly outperforming the iShares Biotechnology ETF, which is up approximately 3% [1] Group 2: Disruption Mechanisms - While biotech firms are insulated from AI-driven disruption, they face challenges such as patent cliffs, biosimilar competition, and government drug pricing reforms [1] - AbbVie’s Humira lost exclusivity, leading to a revenue drop of about 50% in two years, highlighting the risks associated with patent cliffs [1] - Amgen's revenue from Enbrel fell 48% in Q4 2025 due to biosimilar competition and Medicare redesign, indicating structural revenue erosion [1] Group 3: Company-Specific Insights - Gilead's ASCENT-07 trial for Trodelvy missed its primary endpoint, demonstrating how clinical trial failures can significantly impact pipeline value [2] - Eli Lilly's stock has appreciated approximately 416% over five years, driven by the success of its GLP-1 products, but it is down 6% year-to-date in 2026 [2] - Biogen's revenue is expected to decline mid-single digits in 2026, with its MS franchise down 14% in Q4 2025, reflecting a different risk profile compared to other biotech firms [2] Group 4: Evaluating Biotech Stocks - Investors should assess biotech stocks based on three questions: the percentage of revenue from products with patent protection beyond five years, the presence of at least two Phase 3 pipeline products, and the strength of the balance sheet to support pipeline investments [2] - Amgen's CEO expressed confidence in the company's broad portfolio and innovative therapies, indicating a path for sustained long-term growth [2] - Understanding the specific types of disruption, such as patent cliffs and pricing reform, is crucial for investors to navigate volatility in the biotech sector [2]

Core Viewpoint - AbbVie reported strong fourth-quarter earnings, with adjusted EPS and revenues exceeding expectations, driven by robust sales of key drugs, although facing challenges from Humira's generic erosion and declining sales in certain segments [2][3][7]. Financial Performance - Fourth-quarter 2025 adjusted EPS was $2.71, beating the Zacks Consensus Estimate of $2.66 and the company's guidance of $2.61-$2.65, with earnings rising over 25% year over year [2]. - Revenues reached $16.62 billion, surpassing the Zacks Consensus Estimate of $16.36 billion and the company's guidance of $16.3 billion, reflecting a 10% year-over-year increase [2]. - Full-year 2025 sales rose 8.6% to $61.16 billion, exceeding the Zacks Consensus Estimate of $60.93 billion [21]. Drug Performance - Key drugs such as Rinvoq, Skyrizi, Venclexta, and Vraylar contributed significantly to revenue growth, while Humira faced a 26% sales decline due to biosimilar competition [3][7]. - Skyrizi sales were $5.01 billion, up 31.9% year over year, while Rinvoq sales reached $2.37 billion, up nearly 28.6% [4][5]. - AbbVie's ex-Humira drugs saw a 14.5% increase in sales, driven by strong performance in immunology and neuroscience [3]. Future Outlook - For 2026, AbbVie expects total revenues of $67 billion, representing a growth of approximately 9.5%, driven by Skyrizi and Rinvoq sales, alongside a substantial ramp for Vyalev [22]. - The company anticipates adjusted EPS in the range of $14.37-$14.57 for 2026, excluding impacts from acquired IPR&D expenses [22]. - Global immunology sales are projected to reach $34.5 billion in 2026, with Skyrizi and Rinvoq expected to generate significant revenue [8]. Cost and Margin Analysis - Adjusted gross margin was 83.6% in the quarter, with adjusted SG&A expenses rising 4% year over year to $3.71 billion [20]. - Adjusted operating margin was 38.3%, reflecting a 7.6% unfavorable impact from acquired IPR&D expenses [20]. Market Position and Competitors - AbbVie holds a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [29]. - The company is positioned within the Zacks Large Cap Pharmaceuticals industry, where competitors like Pfizer have also reported mixed results [30].

Core Viewpoint - AbbVie is a large pharmaceutical company with a diverse product portfolio, and its attractive dividend yield of 2.9% makes it appealing to dividend investors [1][2]. Dividend Yield Comparison - AbbVie's dividend yield of 2.9% is significantly higher than the S&P 500's yield of 1.1% and the average pharmaceutical company's yield of 1.7%, providing investors with 1.8 percentage points more than the broader market and 1.2 percentage points more than the average drug stock [2]. Dividend Sustainability - AbbVie has a history of reliable dividend growth, with a 200% increase over the past decade, indicating a strong commitment to rewarding investors [4]. - The payout ratio exceeds 100%, but when considering the cash dividend payout ratio, which is around 60%, the sustainability of the dividend appears more favorable [5]. Business Stability - AbbVie's esthetics business, particularly Botox, offers a stable cash flow foundation despite the loss of patent protection, suggesting resilience against typical patent cycle impacts faced by other drugmakers [6]. Investment Potential - AbbVie presents an opportunity for healthcare diversification in dividend portfolios, with an attractive yield and potential for a growing dividend stream, making it a solid choice for long-term, income-focused investors [7].

Core Insights - Johnson & Johnson (JNJ) and AbbVie (ABBV) are prominent pharmaceutical companies with strong positions in immunology, oncology, and neuroscience, alongside J&J's extensive medical devices business [1] - Both companies are facing patent challenges, necessitating effective pipeline execution and business development for sustained growth [2] Company Overview Johnson & Johnson (JNJ) - JNJ's diversified business model includes pharmaceuticals and medical devices, with over 275 subsidiaries and 28 products generating over $1 billion in annual sales [4] - The Innovative Medicine unit showed a 4.1% organic sales growth in 2025, driven by key drugs like Darzalex and new products [5] - JNJ's MedTech business saw a 4.3% organic sales increase in 2025, supported by acquisitions and improvements in various segments [6] - Significant R&D investments exceeding $32 billion in 2025, with new product approvals expected to drive future growth [7] - JNJ anticipates that 10 new products could achieve peak sales of $5 billion each [8] AbbVie (ABBV) - AbbVie successfully transitioned from the loss of exclusivity (LOE) of Humira by launching new immunology drugs, Skyrizi and Rinvoq, which contributed to a combined sales growth of over 40% in 2025 [9][10] - The neuroscience portfolio also saw a nearly 20% sales increase, driven by products like Botox and Vraylar [12] - AbbVie has invested over $5 billion in acquisitions to enhance its early-stage pipeline, particularly in immunology [13] - The aesthetics segment faced challenges, with global sales declining by 5.9% in 2025 [14] Financial Performance - JNJ's stock rose 48% in the past year, while AbbVie's stock increased by 10.2%, both outperforming the industry average of 12.1% [20] - The Zacks Consensus Estimate for JNJ's 2026 sales and EPS indicates a year-over-year increase of 6.5% and 7.0%, respectively [15] - AbbVie's 2026 sales and EPS estimates imply a year-over-year increase of 9.4% and 8.74%, respectively [17] Valuation and Yield - AbbVie appears more attractive from a valuation perspective, trading at a forward P/E ratio of 15.25 compared to JNJ's 20.79 [20] - AbbVie offers a higher dividend yield of approximately 3.1%, compared to JNJ's 2.1% [23] Future Outlook - AbbVie expects high single-digit revenue growth through 2029, driven by Skyrizi and Rinvoq, with no significant LOE events anticipated [27] - JNJ aims for approximately $100 billion in revenues in 2026, with expectations of sales growth across both segments [28] - Both companies are positioned for continued growth, with JNJ showing a slight edge in stock performance and analyst estimates [29]

Core Insights - AbbVie reported strong fourth-quarter and full-year 2025 results, surpassing expectations, primarily driven by its newer immunology drugs, Rinvoq and Skyrizi, which offset the decline of the legacy drug Humira [1] Financial Performance - Skyrizi and Rinvoq generated combined revenues of approximately $26 billion, reflecting over 40% year-over-year growth. Skyrizi sales increased by 50% year-over-year to $17.56 billion, while Rinvoq sales rose by 39% to $8.30 billion [2] - AbbVie anticipates overall sales to grow at a high single-digit revenue CAGR through 2029, with combined sales of Skyrizi and Rinvoq expected to exceed $31 billion in 2026, surpassing the long-term guidance of $31 billion for 2027 [4] Market Dynamics - The immunology market is experiencing strong growth, with significant market share gains for Skyrizi in psoriasis and Rinvoq in rheumatoid arthritis. New indications for both drugs, including recent approvals and potential future approvals, are expected to drive further growth [3][5] - AbbVie expects Rinvoq to secure approvals for vitiligo and alopecia areata in 2026, with additional phase III data anticipated for hidradenitis suppurativa and systemic lupus erythematosus [5] Competitive Landscape - AbbVie faces competition from Johnson & Johnson, which markets Stelara and Tremfya, and Eli Lilly, which recently received FDA approval for Omvoh in ulcerative colitis [7][8] Valuation and Estimates - AbbVie shares are currently trading at a P/E ratio of 15.14, below the industry average of 18.74, but above its five-year mean of 13.68 [12] - Estimate revisions for 2026 EPS have trended higher, while those for 2027 have decreased over the past 30 days [14]